Stories about Liver function tests
-
Language:
English
-
Media:
All
- Period:
- Period:Total
- more
Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers
moreNew Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
moreCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
moreMerck to Showcase New Data Across MS Portfolio at EAN 2019
moreMerck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
moreMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
morePivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
moreFDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
moreBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
more
1